Entrectinib-associated perimyocarditis in ROS1-positive NSCLC: a diagnostic and therapeutic dilemma — a case report
- 1nd Department of Respiratory Medicine, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland
Abstract
Background and clinical significanceEntrectinib is an effective therapy for ROS1-positive metastatic non-small cell lung cancer (NSCLC), but rare cardiotoxicity can easily be overlooked due to its non-specific presentation.Case presentationWe report the case of a 55-year-old woman with ROS1-positive NSCLC who developed persistent fever and hypotension (85/60 mmHg) after three months of entrectinib, despite achieving excellent tumour regression. Sepsis or neoplastic fever was initially suspected; however, she subsequently developed progressive dyspnoea and acute respiratory failure with rising cardiac biomarkers despite a preserved left ventricular ejection fraction (58%). Multiparametric cardiac magnetic resonance (CMR) findings were consistent with perimyocarditis, and endomyocardial biopsy was not performed. Following drug withdrawal and initiation of therapy for heart failure with preserved ejection fraction (HFpEF) along with colchicine and naproxen for pericardial inflammation, gradual cardiac recovery was achieved, but the tumour rapidly progressed within 13 days (from 22 to 35 mm). Entrectinib was reintroduced at a reduced dose (200 mg daily), yet recurrent cardiopulmonary failure occurred two weeks later, requiring permanent discontinuation.ConclusionsThis case highlights that entrectinib-associated perimyocarditis can mimic infection, emphasizing the role of advanced non-invasive cardiac imaging, particularly CMR, in establishing the diagnosis. It underscores the profound therapeutic challenge of balancing the life-prolonging benefits of targeted oncological therapy against severe, recurrent cardiotoxicity.
Related
- Anti-fibrillarin Positive Systemic Sclerosis Presenting With Myositis and Perimyocarditis
- Natriuretic Peptide Receptor-C (NPR3) in Pulmonary Hypertension Associated with Chronic Lung Disease: A PRISMA-ScR Scoping Review of Diagnostic, Prognostic, Mechanistic, and Therapeutic Evidence
- Novel variant and enteroendocrine hormone deficiency in a patient with proline and glutamate‐rich protein with a coiled coil domain 1 (PERCC1) associated enteropathy: New diagnostic and therapeutic insights
- Colonic Mucosa-Associated Lymphoid Tissue Following Prior Hodgkin Lymphoma: A Diagnostic Challenge and Therapeutic Approach – A Case Report
- Case Report: Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder: Diagnostic Challenges and Transition From B‐Cell Depletion Therapy to Ravulizumab
BibTeX
@article{soltysiak2026entrectinibassociated,
title = {{Entrectinib-associated perimyocarditis in ROS1-positive NSCLC: a diagnostic and therapeutic dilemma — a case report}},
author = {Malwina Sołtysiak and Paweł Śliwiński},
journal = {Frontiers in Medicine},
year = {2026},
month = nov,
doi = {10.3389/fmed.2026.1997512},
url = {https://doi.org/10.3389/fmed.2026.1997512},
note = {CC BY},
}
RIS
TY - JOUR
TI - Entrectinib-associated perimyocarditis in ROS1-positive NSCLC: a diagnostic and therapeutic dilemma — a case report
AU - Malwina Sołtysiak
AU - Paweł Śliwiński
PY - 2026
DA - 2026/11/06
JO - Frontiers in Medicine
DO - 10.3389/fmed.2026.1997512
UR - https://doi.org/10.3389/fmed.2026.1997512
AB - Background and clinical significanceEntrectinib is an effective therapy for ROS1-positive metastatic non-small cell lung cancer (NSCLC), but rare cardiotoxicity can easily be overlooked due to its non-specific presentation.Case presentationWe report the case of a 55-year-old woman with ROS1-positive NSCLC who developed persistent fever and hypotension (85/60 mmHg) after three months of entrectinib, despite achieving excellent tumour regression. Sepsis or neoplastic fever was initially suspected; however, she subsequently developed progressive dyspnoea and acute respiratory failure with rising cardiac biomarkers despite a preserved left ventricular ejection fraction (58%). Multiparametric cardiac magnetic resonance (CMR) findings were consistent with perimyocarditis, and endomyocardial biopsy was not performed. Following drug withdrawal and initiation of therapy for heart failure with preserved ejection fraction (HFpEF) along with colchicine and naproxen for pericardial inflammation, gradual cardiac recovery was achieved, but the tumour rapidly progressed within 13 days (from 22 to 35 mm). Entrectinib was reintroduced at a reduced dose (200 mg daily), yet recurrent cardiopulmonary failure occurred two weeks later, requiring permanent discontinuation.ConclusionsThis case highlights that entrectinib-associated perimyocarditis can mimic infection, emphasizing the role of advanced non-invasive cardiac imaging, particularly CMR, in establishing the diagnosis. It underscores the profound therapeutic challenge of balancing the life-prolonging benefits of targeted oncological therapy against severe, recurrent cardiotoxicity.
SN - 2296-858X
ER -